Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Subviral Agents01:29

Subviral Agents

580
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
580
Air-entraining Agents01:27

Air-entraining Agents

276
Air-entraining agents improve the durability and workability of concrete in climates with frequent freezing and thawing. These agents prevent cracks by introducing small air bubbles into the mix, creating spaces accommodating water expansion when temperatures drop. The air-entraining agents lower the surface tension of water, forming stable, small air bubbles. This method is more effective than having accidental large voids, as the intentional, smaller, and evenly distributed air voids improve...
276
Masking and Demasking Agents01:19

Masking and Demasking Agents

3.6K
EDTA titrations may necessitate masking and demasking agents to temporarily protect a particular metal ion in a mixture from the EDTA reaction. These agents facilitate the sequential analysis of the metal ions by forming stable complexes with some—but not all—metal ions during certain steps.
There are many masking agents, such as cyanide, fluoride, triethanolamine, thiourea, and 2,3-bis(sulfanyl)propan-1-ol (formerly 2,3-dimercapto-1-propanol), with the masking agent chosen based on...
3.6K
Spasmolytic Agents: Chemical Classification01:29

Spasmolytic Agents: Chemical Classification

1.3K
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
1.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

681
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
681
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

1.7K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The evolving understanding of prurigo nodularis.

Clinical and experimental dermatology·2026
Same author

Publisher Correction: A 98-qubit trapped-ion quantum computer with all-to-all connectivity.

Nature·2026
Same author

Restoring balance in atopic disorders: insights into type 2 immunity and chronic inflammation.

Frontiers in immunology·2026
Same author

A 98-qubit trapped-ion quantum computer with all-to-all connectivity.

Nature·2026
Same author

Neuronal responses to cytokines limit intestinal hypermotility and systemic effects of colonic inflammation.

iScience·2026
Same author

Correction: Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria.

Dermatology and therapy·2026

Related Experiment Video

Updated: Feb 8, 2026

Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

560

Immunomodulating Agents as Antipruritics.

Stephen Erickson1, Zachary Nahmias1, Ilana S Rosman2

  • 1Division of Dermatology, Department of Medicine, Washington University School of Medicine, 660 South Euclid Campus Box 8123, St Louis, MO 63110, USA.

Dermatologic Clinics
|June 23, 2018
PubMed
Summary
This summary is machine-generated.

Chronic pruritus (itch lasting >6 weeks) is a growing problem. New research shows neuroimmune pathways cause itch, leading to novel biologic therapies for conditions like atopic dermatitis and chronic urticaria.

Keywords:
Atopic dermatitisChronic idiopathic pruritusImmunomodulatorItchPrurigo nodularisPruritusUrticaria

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.2K
Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging
11:27

Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging

Published on: December 4, 2016

10.6K

Related Experiment Videos

Last Updated: Feb 8, 2026

Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

560
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.2K
Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging
11:27

Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging

Published on: December 4, 2016

10.6K

Area of Science:

  • Immunology
  • Neuroscience
  • Dermatology

Background:

  • Chronic pruritus, defined as itch lasting over six weeks, is a prevalent and disabling condition.
  • Emerging research highlights neuroimmune axes where inflammatory cytokines directly stimulate the nervous system, causing itch.
  • This understanding opens avenues for novel therapeutic strategies targeting chronic itch disorders.

Purpose of the Study:

  • To review the pathophysiology of various chronic itch disorders.
  • To discuss emerging immunomodulatory therapies for chronic itch.
  • To explore how these therapies may change current treatment approaches.

Main Methods:

  • Review of current literature on chronic pruritus pathophysiology.
  • Analysis of emerging immunomodulatory and biologic therapies.
  • Discussion of treatment paradigms for atopic dermatitis, chronic idiopathic pruritus, chronic urticaria, and prurigo nodularis.

Main Results:

  • Identification of key neuroimmune pathways involved in chronic itch.
  • Overview of targeted biologic therapies acting on these pathways.
  • Discussion of the potential impact of new therapies on treatment.

Conclusions:

  • Chronic pruritus involves complex neuroimmune interactions.
  • Targeted biologic and immunomodulatory therapies offer promising new treatment options.
  • These advancements are expected to significantly alter the management of chronic itch disorders.